I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma Journal Article

  


Authors: Carrasquillo, J. A.; Pandit-Taskar, N.; Chen, C. C.
Article Title: I-131 metaiodobenzylguanidine therapy of pheochromocytoma and paraganglioma
Abstract: Pheochromocytomas and paragangliomas are rare tumors arising from chromaffin cells. Available therapeutic modalities consist of chemotherapy, tyrosine kinase inhibitors, and I-131 metaiodobenzylguanidine (MIBG). I-131 MIBG is taken up via specific receptors and localizes into many but not all pheochromocytomas and paragangliomas. Because these tumors are rare, most therapy studies are retrospective presentations of clinical experience. Numerous retrospective studies and a few prospective studies have shown favorable responses in this disease, including symptomatic, biochemical, and objective responses. In this report, we review the experience of using I-131 MIBG therapy for targeting pheochromocytoma and paragangliomas. © 2016 Elsevier Inc. All rights reserved.
Journal Title: Seminars in Nuclear Medicine
Volume: 46
Issue: 3
ISSN: 0001-2998
Publisher: Elsevier Inc.  
Date Published: 2016-05-01
Start Page: 203
End Page: 214
Language: English
DOI: 10.1053/j.semnuclmed.2016.01.011
PROVIDER: scopus
PUBMED: 27067501
DOI/URL:

https://www.scopus.com/inward/record.url?eid=2-s2.0-84962875281&partnerID=40&md5=28b293b322ea54476931cd3d813e3e1a
Notes: Review -- Export Date: 2 May 2016 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Neeta Pandit-Taskar
    342 Pandit-Taskar
  2. Jorge Carrasquillo
    140 Carrasquillo
Related MSK Work